FSD Pharma

Advancing Cannabinoid Pharmaceutical R&D to Address Unmet Medical Needs

This FSD Pharma profile is part of a paid investor education campaign.*

Overview

FSD Pharma (CSE: HUGE, NASDAQ:HUGE, FRA:0K9) is a specialty biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract and the musculoskeletal system. Through its acquisition of Prismic Pharmaceuticals in Q2 2019, FSD Pharma is also making an effort to help address the opioid crisis by developing opioid sparing prescription drugs utilizing the micronized formulations of palmitolylethonalamide (PEA). The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under Canada’s Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. The Company is licensed to cultivate cannabis in approximately 25,000 square feet of its facility in Cobourg, Ontario.

FSD Pharma has established strategic alliances with World Class Extractions Inc. (CSE: PUMP), High Tide Inc. (CSE: HITI), SciCann Therapeutics, Canntab Therapeutics Ltd. (CSE: PILL), Cannara Biotech (CSE: LOVE), Solarvest BioEnergy, Huge Shops and Aura Health Inc. (CSE: BUZZ).

FV Pharma is a licensed producer under the Cannabis Act and received its full sale for medical purposes license in June 2019.

FSD Pharma Company Highlights

  • Biotech pharmaceutical company focused on R&D of cannabinoid-based treatments to address unmet medical needs.
  • Recent acquisition of Prismic Pharmaceuticals
  • Strategic alliances in place with SciCann, High Tide, Canntab, Cannara, World Class Extractions , Solarvest BioEnergy, Huge Shops and Aura Health.
  • Ongoing cannabinoid-based studies with SciCann.
  • ACMPR licensed producer, operating under the recently enacted Cannabis Act.
  • 100 percent ownership of former Kraft Foods facility measuring 70 acres, with 40 acres primed for development.
  • The latest cultivation technologies are to be employed at the facility.
  • Experienced executives and Advisory Board of leading researchers.

FSD Pharma’s Business Model

FSD Pharma is focused on researching and developing novel prescription cannabinoid-based therapeutic products for the US and other markets. The acquisition of Prismic and the partnership with SciCann allows FSD Pharma to develop cannabinoid-based therapies and treatments for many ailments. As part of the company’s cannabinoid-based pharmaceutical platform, FSD Pharma intends to develop proprietary technologies and intellectual property (IP) by conducting clinical trials through Prismic Pharmaceuticals and its strategic partner SciCann.

Through its subsidiary FV Pharma, the company is also committed to growing pharmaceutical-grade cannabis for the medicinal market. The company aims to maximize production and optimize efficiencies at its 25,000-square foot indoor cannabis cultivation facility.

The former ‘KRAFT’ Cobourg Facility

FSD Pharma’s cannabis production facility is located in Cobourg, Ontario, only one hour east of Toronto. The company is retrofitting the former Kraft Foods facility which sits on a 70-acre parcel of land. FSD Pharma received its standard processing and full sales licenses for the facility from Health Canada in 2019.

Thanks to its proximity to a metropolitan hub, the facility is easily accessible and is supported by sufficient infrastructure to conduct its operations. In addition to the necessary security, the building has an on-site electrical substation that provides enough power for 9,000 1,000-watt grow bulbs, multiple natural gas lines, 26 loading docks and a 24-inch main sewage pipe. Additionally, the facility’s proximity to Toronto is another cost-saving advantage. By consolidating operations under one roof, FSD Pharma has access to greater economies of scale and the ability to reduce costs.

Prismic Pharmaceuticals

Prismic Pharmaceuticals was acquired by FSD Pharma in June 2019 and forms part of the FSD Pharma BioSciences division. Prismic is a US-based specialty pharmaceutical company dedicated to developing novel non-addictive prescription drugs for the treatment of pain and inflammation.

Prismic has the worldwide rights (except for Italy and Spain) for micro-PEA (palmitoylethanolamide). PEA is a naturally occurring anti-inflammatory that is produced within human cells in response to inflammation. Micronization allows PEA to be orally bio-available. The micronization technique was invented by Epitech and is protected by patents until 2030.

As a potent analgesic and anti-inflammatory agent, micro-PEA is expected to be effective in many inflammatory diseases such as chronic pain, arthritis, endometriosis, and various auto-immune disorders. In addition, there is some published data to suggest that micro-PEA may also have the potential to be an opioid-sparing agent.

FSD Pharma’s Strategic Alliances

Cannara Biotech – Strategic Investment in Montreal, Quebec

FSD Pharma has invested in Cannara Biotech, which plans to be the largest indoor cultivation facility in Quebec. Cannara purchased a modern 625,000-square-foot facility on 27 acres of land, located less than one-hour drive from Montreal. FSD Pharma has an equity investment of 85,003,750 Class B shares of Cannara.

CannTab Therapeutics – Collaboration and Profit-Sharing Agreement in Markham, Canada

Canntab Therapeutics was founded on April 20, 2016 by pharmaceutical industry professionals who saw an urgent need to add industry rigor and professionalism to the medicinal cannabis market. CannTab is the first company solely dedicated to research and development of oral dosage therapeutic formulations of cannabis. The company developed a unique, patent pending technology which resulted in the creation of a range of oral dosage products that effectively treat different ailments by delivering a uniform dosage of medicinal cannabis extract.

SciCann Therapeutics – Strategic Partnership in Tel Aviv, Israel

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.

World-Class Extractions – Collaboration and License Agreement in Toronto, Canada

World-Class Extractions provides precision single step mobile extraction services using patent pending technologies that produce higher yields of crude at faster rates. World-Class Extractions can save its clients floor space, process fees, utility fees, equipment cost and more, including minimizing by-product plant biomass produced and materials used in extraction recovery.

High Tide Inc. – Strategic Investment in Alberta and Saskatchewan

High Tide is an Alberta-based, downstream cannabis corporation focused on the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Famous Branz Inc., Kush West Distribution Inc., Smoker’s Corner Ltd., Grasscity.com, Canna Cabana Inc. and the majority of Kush Bar Inc. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

Solarvest – Collaborative Research Agreement

FSD Pharma has signed a LOI with Solarvest to develop and test pharma-grade cannabinoids out of algae. The pharma-grade process could reduce the production time for targeted cannabinoid molecules by up to 95 percent. Solarvest is an algae technology company whose production platform provides it with an extremely flexible system capable of being adapted to produce numerous products. The company has completed a feasibility study for the expression of CBD and THC as a way to produce cannabinoids in sterile GMP facilities.

Huge Shops – Toronto, Ontario

FSD Pharma has completed a strategic investment in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide.

As part of the investment, Huge Shops has the option to acquire a minimum of 10 retail locations under Chairman’s umbrella of properties, and, subject to availability and further negotiation, purchase additional Coffee Time sites. FSD Pharma’s investment in Huge Shops’ is expected to enable the company to quickly create a network, with a well-established consumer base of 14 million consumers, in key demographic areas throughout Ontario.

Aura Health

FSD Pharma has completed a share exchange transaction with Aura Health (CSE:BUZZ), a Toronto-based medical cannabis company that is building a global network of vertically-integrated businesses. FSD Pharma acquired 13.56 million shares valued at $3 million from Aura Health.

FSD Pharma’s Management

Dr. Raza Bokhari – Executive Co-Chairman of the Board and CEO

Recipient of Philadelphia Business Journal’s “40 under 40” award, physician turned entrepreneur, Dr. Raza Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. An effective “change agent”, with several years of experience and expertise in start-up and turn-around businesses, he has a special knack of adeptly turning around financially struggling companies. Over the years, he has come to realize the special role of private equity funds, venture capital money and leveraged debt partners in executing accelerated growth trends in healthcare services and cancer diagnostics and therapeutics.

Dr. Bokhari has also spoken before professional organizations and academic institutions, including the US Congressional Caucus. He has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College and an Executive MBA from Temple University, Fox School of Business & Management. He currently serves as the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, is the managing partner of RBx Capital, LP and is a board member for Akers Biosciences.

Anthony Durkacz – Executive Co-Chairman of the Board and Founder

Anthony Durkacz is currently a Director and Executive Vice President at First Republic Capital Corp. since January 2014. First Republic Capital Corp. has acted as the exclusive agent of the company and has raised approximately $53 million in equity capital to date. Previously, he was President of Capital Ideas Investor Relations from January to December 2013. Before that he was a Director and CFO of Snipp Interactive Inc. (TSXV: SPN) from January 2011 to January 2013. He was instrumental in the financing and public listing of the mobile marketing company with operations in Canada, the USA, Mexico and India.

Durkacz is also the owner and President of Fortius Research & Trading Corp., which provides financial and investor relations consulting services to micro and small cap companies in various sectors, and develops investment strategies for high net worth individuals. From 2006 to 2009, he served as COO and CFO of MKU Canada Inc. engaging in mergers and acquisitions globally, and from 2002 to 2006 he served as the CFO of Astris Energi Inc., a dually listed public company in the USA and Canada which was acquired by an international conglomerate. He began his career at TD Securities on the capital markets trading floor. Durkacz holds an Honors Bachelor of Business Administration from Brock University with a major in both Accounting and Finance.

Zeeshan Saeed – President, Founder, and Director

Zeeshan Saeed is an entrepreneur and is one of the founding members of FV Pharma Inc, which is now wholly owned by FSD Pharma Inc. He has been involved with the company from the beginning since July of 2013. Saeed has provided consulting advice to FV Pharma and was instrumental for raising the initial seed capital. He played a key role in bringing together a team of professionals in the development of the corporation’s business plan as well as bringing key relationships to the company. He has experience in international capital markets and has helped various startups with the process of raising initial funding and getting listed on various stock exchanges.

Saeed is an engineer by qualification and is currently President and Director of FSD Pharma Inc. Before entering the capital markets, Saeed was the founder and CEO of Platinum Telecommunications Inc., which was eventually taken over by a public company.

Donal Carroll, CPA – CFO

Donal Carroll joined FSD Pharma as interim Chief Financial Officer in 2018 and was appointed to the position on a permanent basis in December 2019. An experienced business executive, Carroll has 20 years of corporate finance leadership and public company experience, as well as deep expertise in syndicate investing both in equity and debt securities. With a balance of prudent financing practices and business insights, Mr. Carroll has successfully guided companies through expansion and growth.

Carroll was previously with Danaher, Alberto Culver (now Unilever (NYSE:UL) and Cardinal Meats, where he was instrumental in major restructuring activities, mergers and acquisitions and the implementations of new internal controls and ERP systems resulting in significant efficiencies through periods of substantial change and strong company growth. Carroll has been a Director of Bird River Resources Inc., since September 15, 2017. He also serves on the Board of Directors of World-Class Extractions (CSE: PUMP), where he is the Chairman of the Audit Committee.

He holds a CPA-CMA designation as well as a Bachelor of Commerce degree from University College Dublin.

Dr. Sara May, Ph.D. – FV Pharma Inc. President

Dr. Sara May is a Ph.D. graduate with a multidisciplinary background in plant breeding and crop genetics with over 10 years’ experience designing, implementing and managing large-scale projects in the field, lab and greenhouse. She has extensive work experience with all aspects of national, international, provincial and regional legislative acts and regulations. Dr. May has deep domain expertise in the medical cannabis industry, which includes managing large-scale operations, developing and implementing quality control and quality assurance methods and standard operating procedures and HACCP.

She has prior experience in the US growing and producing high-quality medical cannabis in California. She was responsible for cloning, up-keep, harvesting, processing and selling product into licensed dispensaries. Dr. May designed a specialized crop breeding program and successfully developed two new strains of cannabis. Dr. May has co-authored 10 peer-reviewed published manuscripts and is an active peer reviewer for national and international scientific journals.

Shahzad Shah – FV Pharma Inc. COO

Mr. Shah is a seasoned executive with nearly three decades of executive leadership experience working for public and private corporations in North America. He brings a wealth of experience, with particular strengths in areas such as building results-oriented teams that have turned around existing companies, assembled teams that have launched successful companies in North America, planned both financial and operational strategies and was part of the leadership team that crafted and executed strategy for a $2 billion organization.

In his various executive roles, he has managed and driven continuous improvement initiatives for multifacility divisions across North America introducing Lean Methodologies and sharing best practices. In his last role he was responsible for overseeing continuous improvement initiatives and managed a P&L of $500 million in revenue.

Shah holds an MBA from Queen’s University, Kingston Ontario, Engineering and Human Resources diplomas from Humber College, Toronto, Ontario, and Master Lean Six Sigma Black Belt from York University. He also holds designation of Certified Management Consultant from the Canadian Association of Management Consultants.

Dr. Edward Brennan Jr., M.D., FACS – FSD BioSciences Division President

Dr. Edward Brennan has over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations. He is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development. Dr. Brennan has extensive experience in all phases of clinical development across multiple therapeutic areas. As a Medical Director with Wyeth-Ayerst Research and GlaxoSmithKline, he led teams through ten IND applications and advanced multiple compounds from pre-candidate selection (proof-of-concept) through clinical trial management and approval. At GSK, he was also responsible for coordinating all clinical activities for external partners within its Center of Excellence in External Drug Discovery. He next founded IndiPharm, a full-service global CRO, that was eventually acquired by private equity company, Velocity Fund Partners.

Dr. Brennan received his undergraduate Bachelor of Science Degree in Pharmacy from the Philadelphia College of Pharmacy and Science. He went on to study Medicine at the Royal College of Surgeons in Ireland before receiving his medical degree from the Temple University School of Medicine.

Zachary Dutton – CEO, Prismic Pharmaceuticals, FSD BioSciences Division

Zachary Dutton is Co-Founder and CEO of Prismic Pharmaceuticals. He has more than 15 years of experience in the pharmaceutical industry and in the commercial development of medical foods. His career has included working with Primus Pharmaceuticals, an innovator in the field of medical foods, where his responsibilities included Business Development, Strategic Planning, and Marketing. Earlier in his career, in addition to managing his own consulting firm, he also managed a nutritional company focused on marketing natural products for maintaining mental health. He holds an MBA from the F.W. Olin School of Business at Babson College and a BA in Economics from Queen’s University in Kingston, Ontario, Canada.

Dr. Sandra Lottes – FSD Biosciences Division Vice President & Head of Clinical Research

Dr. Lottes possesses nearly 30 years of leadership experience in the pharmaceutical, CRO and healthcare industries with extensive multi-disciplinary drug development experience at the program, compound and portfolio levels, expanding across R&D, clinical operations, regulatory affairs, business development and medical affairs. She has held a number of senior executive positions within the pharmaceutical and CRO industries, most recently as Vice President of Global Clinical Development and Operations at United Biosource Corporation, a subsidiary of Express Scripts Inc. (inclusive of legacy Medco Health Solutions), and served as a key member of ESI Pharma Services leadership team, responsible for the largest business unit across multiple global offices.

Dr. Lottes earned an undergraduate degree in biology from the University of Delaware and her doctorate from the Philadelphia College of Pharmacy & Science; she completed her post-doctorate fellowship in cardiovascular pharmacology at Hahnemann University Medical College. Dr. Lottes’ clinical expertise spans the drug development, commercialization and product lifecycle continuum, from early phase registrational research to post-marketing development, including several cardiovascular and GI blockbuster drugs, with a focus on real-world, practical solutions. Sandra has authored many journal articles, abstracts and blogs, and has served on advisory boards in cardiology, gastroenterology, nephrology and biosimilars.

Dr. Larry Kaiser – Chairman of Scientific Advisory Board

Dr. Kaiser is the Dean, Lewis Katz School of Medicine at Temple University, President & CEO of Temple Health System and Senior Executive Vice President for Health Affairs at Temple University in Philadelphia, and was named one of the “50 Most Influential Clinical Executives” for 2019 by Modern Healthcare. Before joining Temple University in 2011, Dr. Kaiser served as the President of the University of Texas Health Science Center at Houston. He graduated from Tulane University School of Medicine and completed a residency in general surgery as well as a fellowship in surgical oncology at UCLA. Dr. Kaiser then completed a residency in cardiovascular and thoracic surgery at the University of Toronto. Following faculty appointments at Memorial Sloan-Kettering Cancer Center and the Washington University School of Medicine, Dr. Kaiser joined the University of Pennsylvania in 1991, where he held positions including Associate Professor of Surgery, Chief of General Thoracic Surgery, Founder and Director of Penn’s Lung Transplantation Program, and Director of its Center for Lung Cancers and Related Disorders. In 2001 he was named the John Rhea Barton Professor and Chairman of the Department of Surgery and the University Health System’s Surgeon-in-Chief.

Dr. Kaiser is the author or co-author of 16 books and more than 300 peer-reviewed papers, and is a member of every major surgical society. In 2005 he was elected to the National Academy of Medicine (formerly the Institute of Medicine of the National Academy of Sciences). His recent honors include citations in Castle Connolly’s America’s Top Doctors for Cancer, Who’s Who in the World and Philadelphia magazine’s “Top Doctors,” among others. Dr. Kaiser maintains time in his schedule at Temple for a limited surgical practice.

Stephen Buyer – Director

Stephen Buyer was a member of the United States House of Representatives, serving nine consecutive terms from January 1993 to January 2011. During Congressman Buyer’s long tenure in the Congress, he served on the Committees on Veterans Affairs, Armed Services, Judiciary, Energy and Commerce Committees and also served on the Military Compensation and Retirement Modernization Commission. He is presently the Managing Partner of the 10-Square Solution, LLC, focusing on business development, mergers and acquisitions, and representation before the federal government.

Congressman Buyer served as Chairman of the Committee on Veterans Affairs for the 109th Congress, as well as the Ranking Minority Member for the 110th and 111th Congresses. He centralized the VA’s IT architecture and was named to the Federal IT top 100. Congressman Buyer also served on the House Armed Services Committee from 1993 to 2001, including as Chair of the Subcommittee on Military Personnel in the 105th and 106th Congresses. He founded and co-chaired the National Guard and Reserve Components Caucus. He created the renewable energy portfolio for the Department of Defense and Veteran Affairs. He was the architect of TRICARE For Life and authored the U.S. military’s pharmacy redesign. His other Congressional assignments included service on the Health, Energy, and Technology subcommittees of the Committee on Energy and Commerce from 2001 to 2010, where he assisted in creating Medicare Part D, authored the electronic pedigree pharmaceuticals distribution system, served as a House Conferee on the Telecommunications Act of 1996, and lead the Congressional effort to reorganization of the U.S. Olympic Committee. He also served the House Committee on Judiciary from 1993 to 1999.

Congressman Buyer, as an Army Reserve officer, served four years on active duty, including a tour of duty in Iraq during the first Gulf War (1990-91) where he was awarded the Bronze Star as an Operational Law Judge Advocate. Prior to JAG, he was a Medical Service Corps Officer for 4 years. Congressman Buyer, after 30 years of service, retired with the rank of Colonel in the U.S. Army Reserve Judge Advocate General Corps. Prior to his tenure in the United States Congress, Congressman Buyer served as a Special Assistant United States Attorney, Indiana Deputy Attorney General, and engaged in a private law practice. Congressman Buyer is a distinguished military graduate of The Citadel in 1980 with a B.S. degree, and received his J.D. from Valparaiso University School of Law in 1984. He is a member of the Indiana and Virginia state Bars.

Robert J. Ciaruffoli, CPA – Director

Robert J. Ciaruffoli is a co-founder and vice-chairman of Broad Street Angels, a 100-member Philadelphia-based angel investor network which invests in start-up entrepreneurial businesses with high growth potential. Broad Street Angels is the largest angel investor network in the Philadelphia region.

He is a CPA and served as the chairman and CEO of the Parente Beard/Baker Tilly accounting and advisory firm. During his tenure as chairman and CEO, he and his team transitioned the firm from a Pennsylvania practice to a multi-state super-regional firm. In 2014, he orchestrated a merger of the Parente Beard and Baker Tilly Virchow Krause firms to create the twelfth largest US accounting and advisory firm. He also served on the board of directors and executive committee of Baker Tilly International, the eighth largest global accounting network. During his tenure on the board and the executive committee, Baker Tilly International grew from an unranked network to the eighth largest global accounting network.

Throughout his career, Ciaruffoli has served on numerous for-profit and not-for-profit boards. Presently, he is the President of the board of directors of The Pennsylvania Society, a board member of Ben Franklin Technology Partners, a board member of eureQa – a SaaS cloud based automated platform for testing digital applications, and a member of the finance committee of the Archdiocese of Philadelphia. He was also the past chairman of the Pennsylvania State Board of Accountancy. He holds a Bachelor of Science in Accounting from Kings College, Wilkes-Barre, Pennsylvania and has proudly served in the US Marine Corps (1970 to 1972).

James A Datin – Director

Over the course of his 30-year career, James Datin has been a successful CEO, raised capital for entrepreneurs to grow companies and managed companies throughout the US, Europe and Asia. He has also completed over 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements.He is the current President & CEO of BioAgilytix, a leading global bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics. Since he became CEO, BioAgilytix has grown its customer base and significantly increased its facility footprint and capacity, including expansion to Europe with the acquisition of Hamburg-based laboratory IPM Biotech. With his leadership, the company has been named to the Inc. 5000 list of Fastest Growing Private Companies in America six times, was named CRO of the Year in North Carolina and has achieved industry-leading customer satisfaction as measured by an independent marketing firm. BioAgilytix was recently acquired by Cobepa, a PE fund.

Datin was previously EVP and Managing Director at Safeguard Scientifics, Inc., where he led the deal and investment team. He was also CEO of Touchpoint Solutions and is a former board member of Intralinks, where he chaired the audit committee. The company was acquired by TA & Associates. He was also Chairman of the Board for five years at Clarient, a cancer diagnostics company, when it was acquired by GE Healthcare in December 2010. In addition, he was Chairman of the Board of Laureate Pharma. Datin holds an Advanced Management Degree from the Wharton School at The University of Pennsylvania, a Master of Business Administration Degree from the University of New Haven and a Bachelor of Business Administration Degree from Marshall University.

Gerald Goldberg, CPA, CA – Director

Gerald Goldberg has over 30 years of experience in the service, distribution, retail, mining, natural resources, oil and gas, real estate, not-for-profit entities and manufacturing industries, with a strong emphasis in taxation and business advisory services. He served as a Partner in the predecessor firm of Grant Thornton for over 15 years before he headed the U.S. Public Company audit division of Academy Capital Corp. Goldberg has served in various roles at the following companies: Gravitas Financial Inc., Gilla Inc., Capricorn Business Acquisitions Inc., Baymount Inc., Blue Nordic Partners Inc., Leo Acquisitions Corp., InterAmerican Gaming Inc., Grasslands Entertainment Inc., Pinetree Capital Ltd., Prime City One Capital Corp., Emerge Resources Corp., Victory Capital Corp., Lakeside Minerals Inc. and Keyuan Petrochemicals Inc.

David Urban – Director

Driven leader and board member with comprehensive accomplishments leading corporate development, government affairs, coalitions, legislative influence, political campaigns and cross-functional teams to achieve goals. Known as an innovative thinker with strong telecommunications, finance, health care, technology, defense, legal, trade and energy acumen. Demonstrated success advising leaders at the highest level of business and government in complex, regulated organizations. Recognized influencer and thought leader that is regularly cited by CNN, New York Times, Washington Post and other leading media outlets. Enables businesses to maximize performance by implementing appropriate strategies through analysis of details to gain understanding of the competitive position, emerging issues, trends and relationships. Continued progression of leadership advising Fortune 100 C-level executives, the president of the United States, members of congress and leading a top government relations firm. Awarded the Bronze Star for action as an Army officer in Iraq.


*Disclaimer: The profile provides information which was sourced and approved by FSD Pharma (CSE: HUGE, NASDAQ:HUGE, FRA:0K9) in order to help investors learn more about the company. FSD Pharma is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on Investingnews.com and channel newsletters.

The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.

INN does not provide investment advice and the information on Investingnews.com profile should not be considered a recommendation to buy or sell any security.

INN does not endorse or recommend the business, products, services or securities of any company profiled.

Readers should conduct their own research for all information publicly available concerning the company.